ReviewInfection and drug resistance2026
Systemic Host Proteomic Signatures as Dynamic Markers for Monitoring Pulmonary Tuberculosis Treatment Response.
Review in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monitoring treatment response of tuberculosis (TB) remains challenging due to the low sensitivity and delayed culture results. Host-derived proteomic biomarker offer a promising alternative by reflecting systemic immune and inflammatory response during therapy. This review aims to systematically evaluate protein-based host biomarkers for monitoring TB treatment response. A systematic search of PubMed and Scopus was conducted for studies published up to September 2025. Eligible studies included human research evaluating protein biomarkers associated with treatment response in adult pulmonary TB. A total of 54 studies comprising 105 distinct biomarkers were included. Biomarkers were grouped into seven categories: acute-phase proteins, inflammatory cytokines, innate immune markers, matrix remodeling enzymes, immune checkpoint molecules, angiogenic factors, and metabolic recovery proteins. Successful treatment was associated with a rapid decline in inflammatory markers followed by modulation of immune and tissue remodeling pathways, while markers of metabolic recovery increased over time. Multi-protein biosignatures demonstrated superior diagnostic performance compared to individual biomarkers. Host-derived proteomic biomarkers provide a dynamic and multidimensional approach to monitoring TB treatment response. While multi-marker signatures show strong potential for clinical application, further standardization, validation, and large-scale studies are required to facilitate their integration into routine TB management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.